The Diabetes-related Kidney Disease Test is an innovative blood test designed to assess future risk of chronic kidney disease (CKD) in adults with type 2 diabetes, providing insight into future kidney disease risk up to four years before symptoms may appear.
Approximately one in two people with type 2 diabetes will develop chronic kidney disease during their lifetime.
Current standard-of-care tests such as estimated glomerular filtration rate (eGFR) and albumin creatinine ratio (ACR) assess current kidney function and kidney damage but may not identify future renal decline.
Early identification of patients at increased risk may support:
Suitable for adults who:
The test measures protein biomarkers associated with kidney disease and combines these results with clinical information, including age and eGFR, to generate an individualised risk score.
Results are reported as:
With corresponding guidance to support clinical management and monitoring decisions.
The Diabetes-related Kidney Disease Test may assist clinicians by:
PromarkerD can be requested by using a standard pathology request form. The test is exclusively available through pathology network and is performed on a routine blood sample.
Results are reported as Low, Moderate or High Risk of future kidney function decline, providing additional information to support monitoring, treatment optimisation and patient management discussions.
Please refer to the clinical guide for eligibility criteria and result interpretation resources.
PromarkerD is currently a privately funded test and is not covered by Medicare. Please refer to current pricing information for patient out-of-pocket costs and payment arrangements.
PromarkerD requires a routine blood sample collected at a participating Laverty Pathology collection centre.
No specialised collection procedure is required. Specimens are transported to the testing laboratory under validated conditions for analysis.
